Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
Pyrophosphoric acid red heat of a sodium phosphate salt. It was found that phosphoric acid when heated to red heat formed pyrophosphoric acid that was readily converted to phosphoric acid by hot water. Pyrophosphoric acid Pyrophosphoric acid, also known under the name diphosphoric acid, is colorless, odorless, hygroscopic and is soluble in water, diethyl ether, and ethyl alcohol. The anhydrous acid has two different forms, which melt at 54.3 °C and 71.5 °C. It is best prepared by ion exchange from sodium pyrophosphate or by reacting hydrogen sulfide with lead pyrophosphate. When phosphoric acid is dehydrated pyrophosphoric acid is produced as one